PT  - JOURNAL ARTICLE
AU  - Ines Abdeljaoued-Tej
TI  - COVID-19 data analysis and modeling in Palestine
AID  - 10.1101/2020.04.24.20078279
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.24.20078279
4099  - http://medrxiv.org/content/early/2020/04/29/2020.04.24.20078279.short
4100  - http://medrxiv.org/content/early/2020/04/29/2020.04.24.20078279.full
AB  - We estimate an actual number of infected cases in Palestine based on the 18-day effect from infection to death. We find that the number of cases in April 22 varies between 506 and 2 026 infected cases. We also focus on the reproductive number in Palestine based on population dynamics with two SEIR models. Dataset is from 5 March to 22 April 2020. With a transmission rate equal to 4.55 10−6, on May 22, the simulations predict 11 014 total infected cases in the optimistic scenario and 113 171 in the worst one. The crest of the pandemic is from 22 to 27 May 2020. The reproductive number ℛ0 is equal to 1.54 for a fixed fraction of 0.6 of symptomatic cases that are reported and for a removal rate of 7. Palestinian COVID-19 mortality number is equal to 6 per million. It is small compared to countries neighboring Palestine. The infected number is equal to 88.4 per million, which is less than most of its neighbors. The basic reproduction number is still greater than 1. Changes to the transmission rate (over time) would be advisable, to fall ℛ0 below the critical threshold.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding support in the work presentedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in https://www.worldometers.info/coronavirus/ and https://corona.ps/details https://www.worldometers.info/coronavirus/